Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025 - Uncover 1,700+ Partnering Deals and Benchmark Deal Structures with Actual Licensing Agreements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025" report has been added to ResearchAndMarkets.com's offering.

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on thousands of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report Scope

Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Companies Featured:

• 2seventy bio
• 3a-diagnostics
• 3B Pharmaceuticals
• 3D Medicines
• 3SBio
• 4D Molecular Therapeutics
• 4SC
• 9 Meters Biopharma
• 23andMe
• Aadi Bioscience
• Abbisko Therapeutics
• Abbott Laboratories
• Abbvie
• AbCellera Biologics
• Abeona Therapeutics
• Abex Pharmaceutica
• ABL Bio
• Ablynx
• Abraxis BioScience
• ABVC BioPharma
• ABX
• ACADIA Pharmaceuticals
• Acceleron Pharma
• Accent Therapeutics
• Accord Healthcare
• Acelrx Pharmaceuticals
• Acer Therapeutics
• Acerus
• AC Immune
• Aclaris Therapeutics
• Acorda Therapeutics
• Acrotech Biopharma
• Actavis (acquired by Watson)
• Actinium Pharmaceuticals
• Active Biomaterials
• Acuitas Therapeutics
• Acumen Pharmaceuticals
• Acura Pharmaceuticals
• Adamis Pharmaceuticals
• Adaptimmune
• AdaptVac
• Adcendo
• ADC Therapeutics
• Adeona Pharmaceuticals
• Adial Pharmaceuticals
• Adimab
• Aditx Therapeutics
• Adlai Nortye
• and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/6wb25h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.